Patients with active systemic lupus erythematosus (SLE) were able to control their disease with Benlysta (belimumab) plus standard of care (prednisone), pharmaceutical giant GSK said in announcing the results from a 10-year continuation study.
GSK presented the study’s results at the Annual European Congress of Rheumatology (EULAR 2017), held June 14-17 in Madrid.
{iframe}https://lupusnewstoday.com/2017/06/19/lupus-therapy-benlysta-achieves-sustained-disease-control-concludes-10-year-gsk-study/{/iframe}